+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Primary Immunodeficiency Disorders Market Size, Share and Trends Analysis Report by Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders), Treatment, and Region 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • September 2024
  • Region: Global
  • Grand View Research
  • ID: 6009709
Description Jump to:
The global primary immunodeficiency disorders market size is expected to reach USD 11.14 billion by 2030. It is expected to expand at a CAGR of 6.4% from 2024 to 2030. The industry is experiencing significant growth, driven by multiple key factors. Rising incidences of genetic disorders, increased awareness among healthcare professionals, and advancements in diagnostic and therapeutic technologies are pivotal in expanding the industry.

A study published in The New England Journal of Medicine in December 2022 highlights the success of gene therapy for Artemis-deficient severe combined immunodeficiency (ART-SCID). By adding a healthy copy of the DCLRE1C gene to patients' stem cells, this therapy effectively restored T and B cell function. The study, involving 10 infants, showed significant immune recovery and reduced complications compared to traditional treatments. Researchers are optimistic about the therapy’s potential, though further long-term studies and broader trials are needed for FDA approval and to explore its applicability in diverse populations. The successful gene therapy for Artemis-deficient SCID boosts industry growth by demonstrating effective treatment for previously difficult-to-treat conditions. This advancement drives demand for gene therapy solutions and innovations in treatments. The positive outcomes from this study potentially leading to increased investment, broader adoption, and the development of new therapies, thereby expanding the industry for advanced treatments.

Moreover, several drug’s success highlights the potential for similar innovations, fostering industry expansion and encouraging further development of specialized therapies in the sector. For instance, in March 2023, Pharming Group leniolisib (Joenja) approved by the FDA as the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) in patients aged 12 and older. The approval follows a 12-week study demonstrating that leniolisib reduced lymph node size and improved naïve B cell counts by 37% compared to placebo. The industry is expanding due to advancements in gene therapy and the approval of new treatments such as leniolisib. These innovations demonstrate effective solutions for previously difficult-to-treat conditions, driving increased investment and interest in the sector. The success ofthese therapies boosts market confidence and encourages further development of specialized treatments. As research progresses and new therapies emerge, the market for advanced immunodeficiency treatments is expected to continue its robust growth, ultimately benefiting patients and healthcare providers alike.

Primary Immunodeficiency Disorders Market Report Highlights

  • Based on region, North America accounted for largest market share of 45.39% in 2023. The market is driven by robust healthcare infrastructure, high prevalence, and proactive government initiatives in the region.
  • Based on disease, antibody deficiency segment accounted for the largest share of 52.62% in disease segment in 2023. The growth can be attributed to its high prevalence, significant healthcare impact, and the development of targeted treatments. Increased awareness and advanced diagnostics also contribute to its substantial presence in the industry.
  • Based on product, the immunoglobulin replacement therapy segment holds the largest share in the market accounted for 63.18% in 2023 owing to its essential role in managing antibody deficiencies. High demand for effective treatment, advancements in therapy, and the critical need for ongoing care contribute to its substantial market share.

The leading players in the Primary Immunodeficiency Disorders market include:

  • Baxter International, Inc.
  • CSL Behring LLC
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • Grifols S.A.
  • Kedrion Biopharma Inc.
  • Bio Products Laboratory Ltd.
  • LFB S.A.
  • ADMA Biologics
  • Astellas Pharma Inc.
  • Abbott Laboratories

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease
1.2.2. Treatment
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease outlook
2.2.2. Treatment outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Primary Immunodeficiency Disorders Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Primary Immunodeficiency Disorders Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Primary Immunodeficiency Disorders Market: Disease Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Primary Immunodeficiency Disorders Market: Disease Movement Analysis
4.3. Primary Immunodeficiency Disorders Market by Disease Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Antibody Deficiency
4.5.1. Antibody Deficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Cellular Immunodeficiency
4.6.1. Cellular Immunodeficiency Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7. Innate Immune Disorders
4.7.1. Innate Immune Disorders Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8. Others
4.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Primary Immunodeficiency Disorders Market: Treatment Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Primary Immunodeficiency Disorders Market: Treatment Movement Analysis
5.3. Primary Immunodeficiency Disorders Market by Treatment Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Immunoglobulin Replacement Therapy
5.5.1. Immunoglobulin Replacement Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Antibiotic Therapy
5.6.1. Antibiotic Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Stem Cell/Bone Marrow Transplantation
5.7.1. Stem Cell/Bone Marrow Transplantation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Gene Therapy
5.8.1. Gene Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Others
5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis
6.1. Regional Dashboard
6.2. Regional Primary Immunodeficiency Disorders Market movement analysis
6.3. Primary Immunodeficiency Disorders Market: Regional Estimates & Trend Analysis by Disease, Biomaterial & End-use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. U.S.
6.5.2.1. U.S. Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Canada
6.5.3.1. Canada Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.4. Mexico
6.5.4.1. Mexico Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.5. Europe
6.5.6. Europe Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.7. UK
6.5.7.1. UK Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.8. Germany
6.5.8.1. Germany Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.9. France
6.5.9.1. France Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.10. Italy
6.5.10.1. Italy Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.11. Spain
6.5.11.1. Spain Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.12. Denmark
6.5.12.1. Denmark Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.13. Norway
6.5.13.1. Norway Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.14. Sweden
6.5.14.1. Sweden Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.2. Japan
6.6.2.1. Japan Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.3. China
6.6.3.1. China Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.4. India
6.6.4.1. India Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. South Korea Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.6. Australia
6.6.6.1. Australia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6.7. Thailand
6.6.7.1. Thailand Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Latin America
6.7.1. Latin America Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.2. Brazil
6.7.2.1. Brazil Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7.3. Argentina
6.7.3.1. Argentina Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Middle East & Africa
6.8.1. Middle East & Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.2. South Africa
6.8.2.1. South Africa Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Saudi Arabia Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.4. UAE
6.8.4.1. UAE Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8.5. Kuwait
6.8.5.1. Kuwait Primary Immunodeficiency Disorders Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Key Company Profiles
7.2.1. Baxter International, Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Disease benchmarking
7.2.1.4. Strategic initiatives
7.2.2. CSL Behring LLC
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Takeda Pharmaceutical Company Limited
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Octapharma
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Biotest AG
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Grifols, S.A.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Kedrion Biopharma Inc
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Bio Products Laboratory Ltd
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. LFB S.A
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. ADMA Biologics, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. Abbott Laboratories
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Astellas Pharma Inc.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 4 Global primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 5 North America primary immunodeficiency disorders market, by region, 2018 - 2030 (USD Million)
Table 6 North America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 7 North America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 8 U.S primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 9 U.S primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 10 Canada primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 11 Canada primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 12 Mexico primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 13 Mexico primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 14 Europe primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
Table 15 Europe primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 16 Europe primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 17 UK primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 18 UK primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 19 Germany primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 20 Germany primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
Table 21 France primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 22 France primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
Table 23 Italy primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 24 Italy primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 25 Spain primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 26 Spain primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 27 Denmark primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 28 Denmark primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
Table 29 Norway primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 30 Norway primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 31 Sweden primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 32 Sweden primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 33 Asia Pacific primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
Table 34 Asia Pacific primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 35 Asia Pacific primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 36 Japan primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 37 Japan primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 38 China primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 39 China primary immunodeficiency disorders market, by treatment 2018 - 2030 (USD Million)
Table 40 India primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 41 India primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 42 Australia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 43 Australia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 44 South Korea primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 45 South Korea primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 46 Thailand primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 47 Thailand primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 48 Latin America primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
Table 49 Latin America primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 50 Latin America primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 51 Brazil primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 52 Brazil primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 53 Argentina primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 54 Argentina primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 55 Middle East & Africa primary immunodeficiency disorders market, by country, 2018 - 2030 (USD Million)
Table 56 Middle East & Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 57 Middle East & Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 58 South Africa primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 59 South Africa primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 62 UAE primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 63 UAE primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
Table 64 Kuwait primary immunodeficiency disorders market, by disease, 2018 - 2030 (USD Million)
Table 65 Kuwait primary immunodeficiency disorders market, by treatment, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information procurement
Fig. 2 Primary research pattern
Fig. 3 Market research approaches
Fig. 4 Value chain-based sizing & forecasting
Fig. 5 Market formulation & validation
Fig. 6 Primary immunodeficiency disorders market segmentation
Fig. 7 Market driver analysis (current & future impact)
Fig. 8 Market restraint analysis (current & future impact)
Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 10 Porter’s five forces analysis
Fig. 11 Primary immunodeficiency disorders market, disease outlook key takeaways, (USD Million)
Fig. 12 Primary immunodeficiency disorders market: disease movement analysis, 2023 & 2030 (USD Million)
Fig. 13 Antibody deficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Cellular immunodeficiency market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 Innate immune disorders market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 16 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 17 Primary immunodeficiency disorders market, treatment outlook key takeaways, (USD Million)
Fig. 18 Primary immunodeficiency disorders market: treatment movement analysis, 2023 & 2030 (USD Million)
Fig. 19 Immunoglobulin replacement therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Antibiotic therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Stem cell/ bone marrow transplantation market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Gene therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Primary immunodeficiency disorders market: regional key takeaways (USD Million)
Fig. 25 Primary immunodeficiency disorders market: regional outlook, 2023 & 2030 (USD Million)
Fig. 26 North America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 US Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Canada Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Mexico Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Europe Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 UK Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Germany Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 France Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Spain Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Italy Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Norway Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Denmark Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Sweden Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Asia Pacific Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 China Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 India Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 South Korea Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Latin America Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Brazil Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Argentina Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Middle East and Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 South Africa Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Saudi Arabia Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 UAE Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Kuwait Primary immunodeficiency disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 List of key emerging company’s/technology disruptors/innovators

Companies Mentioned

The leading players in the Primary Immunodeficiency Disorders market include:
  • Baxter International, Inc.
  • CSL Behring LLC
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Biotest AG
  • Grifols S.A.
  • Kedrion Biopharma Inc.
  • Bio Products Laboratory Ltd.
  • LFB S.A.
  • ADMA Biologics
  • Astellas Pharma Inc.
  • Abbott Laboratories

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedSeptember 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 7.15 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.14 Billion
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Primary Immunodeficiency Therapeutics - Global Strategic Business Report - Product Image

Primary Immunodeficiency Therapeutics - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Subcutaneous Immunoglobulin - Global Strategic Business Report - Product Image

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Primary Immunodeficiency Disorders Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Primary Immunodeficiency Disorders Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Primary Immunodeficiency Therapeutics Market 2024-2028 - Product Image

Primary Immunodeficiency Therapeutics Market 2024-2028

  • Report
  • 136 Pages
  • Global
From
Subcutaneous Immunoglobulin Market by Indication, End-User - Global Forecast 2025-2030 - Product Image

Subcutaneous Immunoglobulin Market by Indication, End-User - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.